A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naive, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer. Article

Web of Science: 001275557400483

Cited authors

  • Christenson E, Mahadevan D, Kazmi SMA, Manda S, Sohal D, Hutson TE, Fu SQ, Martz A, Kordahi S, Barbu EA, Flies D, Langermann S, Chisamore MJ, Gutierrez M, Matrana MR, Spira A, Wadlow RC, Guha U, Myint H, Le DT

Publication date

  • 2024

Published in

International Standard Serial Number (ISSN)

  • 0732-183X

Number of pages

  • 1

Volume

  • 42

Issue

  • 16